欧美日本一道本一区二区_亚洲免费影视_91手机在线看片_精品欧美成人高清在线观看_少妇作爱bbbb免费看_51久久夜色精品国产水果派解说

浙江貝達藥業(yè),Beta Pharma,  
浙江貝達藥業(yè)有限公司成立于2003年1月，是一家由海歸團隊創(chuàng)辦的以自主知識產(chǎn)權(quán)創(chuàng)新藥物研究和開發(fā)為核心，集研發(fā)、生產(chǎn)、營銷于一體的國家級高新制藥企業(yè)。

公司在北京設(shè)有自己的研發(fā)中心，下設(shè)合成室、分析室、藥理室、制劑室、醫(yī)學(xué)部、知識產(chǎn)權(quán)部等，現(xiàn)有90名新藥研發(fā)人員，包括6位留學(xué)歸國博士，他們有深厚的專業(yè)造詣和國際化的新藥開發(fā)理念和實踐經(jīng)驗，特別是他們都有科技報國，振興中國醫(yī)藥事業(yè)，為民造福，實現(xiàn)自己人生價值的使命和愿望。其中兩位博士已入選了中組部“千人計劃”，一名博士入選省級的“千人計劃”，幾位博士先后被評為國家特聘專家、市級特聘專家、“優(yōu)秀博士后”、“先進科技工作者”。

2006年，公司在杭州余杭建立了自己的生產(chǎn)基地，占地40畝，廠房8000㎡，擁有GMP認(rèn)證和片劑和膏劑生產(chǎn)車間和原料藥、腫瘤口服制劑等11個國藥準(zhǔn)字號藥品生產(chǎn)批文。
公司成立9年來，已成功研發(fā)國家1.1 類新藥鹽酸埃克替尼（凱美納），部分完成三個國家一類新藥的臨床前研究，在研新藥項目20多項，獲國內(nèi)、國外專利授權(quán)兩項，申報發(fā)明專利41項，獲科技部創(chuàng)新基金2項、“863”高科技計劃、國家重大新藥創(chuàng)制專項資助3項。已成為我國創(chuàng)新藥研發(fā)的一支新生力量，有望為發(fā)展民族制藥企業(yè)，并逐步走向國際作出相應(yīng)的貢獻。

2010年，公司引進了美國禮來制藥戰(zhàn)略投資，被眾多同行評為“浙商最具投資價值企業(yè)”。

2011年，國家一類新藥鹽酸埃克替尼（凱美納）獲國家食品藥品監(jiān)督管理局頒發(fā)的新藥證書和生產(chǎn)批文，并于7月份正式上市銷售，上市8個月銷售收入即突破1億元人民幣。

貝達藥業(yè)將繼續(xù)秉承創(chuàng)新、開拓為發(fā)展理念，在保持研發(fā)優(yōu)勢的同時，力求建立一支國際化的市場、營銷隊伍，致力于新藥研發(fā)，將創(chuàng)新的成果、福音帶給所有有需要的病人，真正造福國人。

 Zhejiang Beta Pharma is a leading pharmaceutical company primarily focused on the discovery, development and commercialization of new drugs to treat cancer, cardiovascular diseases and diabetes. The company is located in High Tech Park,Hangzhou with R&D center in Beijing.

Zhejiang Beta Pharma is a leading pharmaceutical company with focus on development and commercialization of new drugs for cancer, cardiovascular diseases and diabetes. Conmanna, an EGFR tyrosine kinase inhibitor, for cancer targeting therapy, is our leading compound. The preclinical studies have demonstrated its strong ability to inhibit a varieties of tumor cell growth and very low toxicity to tested animals. The clinical study will start as soon as it gets approval from SFDA.

Beta Pharma has a first-rate research team consisting of 20 multi-disciplined and dedicated professionals, including three American trained doctors. The team has full capacity to carry out the first class research for the new drug development, including chemical synthesis, screening, analysis, scale up, efficacy study, toxicity and safety evaluation and data management. Right now we have three new patented drugs in our pipeline.

We are also processing and marketing generic drugs in collaboration with other pharmaceutical companies including North China Pharma Group. The alliance has dramatically expanded our capacity both for manufacture and marketing.